Literature DB >> 3742456

Carcinoembryonic antigen in primary carcinoid tumors of the lung.

G A Bishopric, N G Ordóñez.   

Abstract

Antibody staining for carcinoembryonic antigen (CEA) was used in 31 cases of primary pulmonary carcinoids to assess the presence of this marker as a parameter of clinical behavior. Other parameters have also been studied (size, position, and histologic characteristics) in order to determine their value as determinants of eventual disease outcome. Tumor size and position did not influence the progression of disease. Atypical histology was a significant predictor (P = 0.05) of treatment failure. Positive CEA marking was the most strongly significant (P = less than 0.01) of all studied parameters for predicting treatment failure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3742456     DOI: 10.1002/1097-0142(19860915)58:6<1316::aid-cncr2820580622>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Management of gastrointestinal carcinoid tumours - 10 years experience at a district general hospital.

Authors:  Shridhar S Dronamraju; Vickram B Joypaul
Journal:  J Gastrointest Oncol       Date:  2012-06

Review 2.  Histopathology and prognostic factors in bronchial carcinoid tumours.

Authors:  P S Hasleton
Journal:  Thorax       Date:  1994       Impact factor: 9.139

3.  Exploration of the pulmonary circulation. Festschrift to Professor Donald Heath.

Authors: 
Journal:  Thorax       Date:  1994       Impact factor: 9.139

4.  Prognostic value of the immunohistochemistry markers CD56, TTF-1, synaptophysin, CEA, EMA and NSE in surgically resected lung carcinoid tumors.

Authors:  Vasiliki Epameinondas Georgakopoulou; Eleftherios Zygouris; Christos Damaskos; Aikaterini Pierrakou; Petros Papalexis; Nikolaos Garmpis; Aikaterini Aravantinou-Fatorou; Serafeim Chlapoutakis; Evangelos Diamantis; Christos Nikokiris; Aikaterini Gkoufa; Pagona Sklapani; Nikolaos Trakas; Jim Janinis; Demetrios A Spandidos; Jubrail Dahabreh
Journal:  Mol Clin Oncol       Date:  2021-12-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.